Sodium Hydroxide → 4-[2-[4-(4-Pyridyl)piperazin-1-yl]acetyl]phenoxyacetic acid

HRID 1291802

Reaktionsgleichung

[N:1]1[CH:6]=[CH:5][C:4]([N:7]2[CH2:12][CH2:11][N:10]([CH2:13][C:14]([C:16]3[CH:27]=[CH:26][C:19]([O:20][CH2:21][C:22]([O:24]C)=[O:23])=[CH:18][CH:17]=3)=[O:15])[CH2:9][CH2:8]2)=[CH:3][CH:2]=1.[OH-].[Na+]>CO.O>[N:1]1[CH:6]=[CH:5][C:4]([N:7]2[CH2:8][CH2:9][N:10]([CH2:13][C:14]([C:16]3[CH:27]=[CH:26][C:19]([O:20][CH2:21][C:22]([OH:24])=[O:23])=[CH:18][CH:17]=3)=[O:15])[CH2:11][CH2:12]2)=[CH:3][CH:2]=1

Komponenten

Reaktionsbedingungen

Temperatur: 4 °C

Versuchsvorschrift

A stirred solution of the product of Example 1 (550 mg) in methanol (10 ml) was treated with a M sodium hydroxide solution (1.65 ml) and stirring continued for a further 2 hours. The mixture was diluted with water (10 ml) and the resulting solution concentrated in vacuo. Water (20 ml) was added and then a M hydrochloric acid solution (1.65 ml). On cooling to 4° C., a solid precipitated. This mixture was concentrated in vacuo, the solid collected and washed with ice-water, then dried to give the title compound, 320 mg, as a solid: m.p. 294°-296° C.; NMR (d6DMSO+TFA) δ 8.34(2H,d), 7.95(2H,d), 7.26(2H,d), 7.10(2H,d), 5.06(2H,s), 4.82(2H,s), 4.06(4H,bs), 3.52(4H,bs); m/e 356(M+H)+ ; calculated for C19H21N3O4 : C, 64.2; H, 6.0; N, 11.8. found: C, 64.1; H, 6.1; N, 11.6%.

Aufarbeitung

concentrationthe resulting solution concentrated in vacuo
additionWater (20 ml) was added
customa solid precipitated
concentrationThis mixture was concentrated in vacuo
customthe solid collected
washwashed with ice-water
customdried

Quellen und Nachweise

ORD-Eintrag: ord-08944e47a33540018a0d74e0941d9046
Quelldatensatz: uspto-grants-1998_05
DOI: 10.6084/m9.figshare.5104873.v1
Patentnummer: US05753659

Verknüpfte Notizen

Wird geladen…